Mein Warenkorb

The BAFF-APRIL Pathway: A Core Regulatory Axis of the TNF Superfamily

The B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), along with their receptors—BAFFR, TACI, and BCMA—constitute a core functional subset of the Tumor Necrosis Factor (TNF) and its receptor superfamilies.
This functionally integrated network is established through specific ligand-receptor binding, and it is crucial for regulating the survival, proliferation, and differentiation of B lymphocytes. Consequently, its dysregulation is closely linked to autoimmune diseases and B-cell malignancies, such as multiple myeloma.
BAFF and APRIL receptor interactions.

BAFF and APRIL receptor interactions.
Resource:DOI: 10.1080/08830185.2016.1276903

Pathological Significance in Disease

The BAFF-APRIL family acts as the core signaling axis for B-cell survival and activation. Dysregulation, such as excessive signal activation, directly compromises immune tolerance, thereby triggering or exacerbating a range of severe diseases:
Autoimmune Diseases B-Cell Malignancies Immunodeficiency Diseases
Overexpression of BAFF/APRIL drives autoreactive B-cell activation and autoantibody production, exacerbating conditions like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
BCMA is highly expressed on multiple myeloma cells, making it a critical target for next-generation therapies like CAR-T and ADCs. Additionally, APRIL overexpression is linked to B-cell lymphoma progression.
BAFFR gene mutations are associated with Common Variable Immunodeficiency (CVID)

Enabling Research and Drug Development

To meet the growing demand for drug development and mechanistic research targeting this vital pathway, we have developed a comprehensive, full-chain product portfolio. This portfolio supports core research scenarios—from disease biomarker discovery to targeted drug development and BAFF pathway mechanism analysis—helping researchers overcome challenges throughout the entire workflow.

Product Features

High Purity verified by SEC-MALS/HPLC.

Native Conformation confirmed by SEC-MALS.

High Bioactivity validated by ELISA/SPR/FACS.

Strict QC Inspection Ensures High Batch-to-Batch Consistency

Product List

BAFF
BAFFR
APRIL
TACI
BCMA
Cat. No.MoleculeNatureProduct DescriptionVorbestellen/Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen
Protein
Bestellen

Validated Data

Trimeric structure verified by SEC-MALS

SDS-PAGE

SDS-PAGE

Biotinylated Human BAFF Protein, His, Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

SEC-MALS

The purity of Biotinylated Human BAFF Protein, His, Avitag (Cat. No. BAF-H82Q2) is more than 90% and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.

Request Report

High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BCMA, Mouse IgG2a Fc Tag (Cat. No. BCA-H5253) at 1 μg/mL (100 μL/well) can bind Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) with a linear range of 0.2-6 ng/mL (QC tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) at 1 μg/mL (100 μL/well) can bind Biotinylated Human TACI, Fc, Avitag (Cat. No. TAI-H82F6) with a linear range of 0.002-0.05 μg/mL (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) at 1 μg/mL (100 μL/well) can bind Biotinylated Mouse BAFFR, Fc, Avitag (Cat. No. BAR-M82F0) with a linear range of 0.4-25 ng/mL (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFFR/BCMA/TACI validated by ELISA

Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF Protein, His, Avitag (Cat. No. BAF-H82Q2) with a linear range of 0.2-4 ng/mL (QC tested).

Request Protocol

High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on CM5 Chip can bind Human TACI Protein, Fc Tag with an affinity constant of 0.658 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Request Protocol
High binding affinity of BAFF to BAFF-BAFFR/TACI validated by SPR

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested). Protocol BAR-H5258

Request Protocol

High binding affinity of BAFF to BCMA validated by BLI

High binding affinity of BAFF to BCMA validated by BLI

Loaded Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on Protein A Biosensor, can bind Biotinylated Human BCMA, His, Avi-tag (Cat. No. BCA-H82E4) with an affinity constant of 0.69 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

BAFF's activity in stimulating mouse splenocyte proliferation verified

BAFF's activity in stimulating mouse splenocyte proliferation verified

Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 4.91-9.81 ng/mL (Routinely tested).

Request Protocol

High binding affinity of APRIL to BCMA/TACI validated by ELISA

High binding affinity of APRIL to BCMA/TACI validated by ELISA

Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) with a linear range of 10-39 ng/mL (QC tested).

Request Protocol
High binding affinity of BAFF to BCMA validated by BLI

Immobilized Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) at 1 μg/mL (100 μL/well) can bind Human TACI Protein, Fc Tag with a linear range of 0.8-25 ng/mL (Routinely tested).

Request Protocol

High binding affinity of APRIL to BCMA/TACI validated by BLI

High binding affinity of APRIL to BCMA/TACI validated by BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol
High binding affinity of APRIL to BCMA/TACI validated by BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human TACI Protein, Fc Tag with an affinity constant of 75 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

Clinical Drug Information Table of BAFF-APRIL Pathway

Englischer NameForschungscodeForschungsphaseFirmaIndikationKlinische Studie
BCMA-UCARTBCMA-UCARTClinicalBRL Medicine IncMultiple Myeloma
Details
bispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology)HRAIN-002ClinicalHrain Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife)ClinicalMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Shanghai GeneChem)ClinicalShanghai Genechem Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit)ClinicalLymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details
APRIL CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
RO-7297089RO-7297089; AFM-26; RG-6296Phase 1 ClinicalGenentech IncMultiple Myeloma
Details
AUR-200AUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma IncAutoimmune Diseases
Details
anti-TriPRIL CAR T-cell therapy(Massachusetts General Hospital)Phase 1 ClinicalMassachusetts General HospitalMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalEugia Pharma Specialities Ltd, Actavis IncMultiple Myeloma
Details
BCMA-CD19 cCARPhase 1 ClinicaliCell Gene Therapeutics LLCLupus Nephritis; Multiple Myeloma; Rejection of organ transplantation; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia
Details
CBG-002CBG-002Phase 1 ClinicalCarbiogene Therapeutics Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Yake Biotechnology/Zhejiang University)Phase 1 ClinicalShanghai Yake Biotechnology Co LtdMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (Kite)FHVH33-CD8BBZPhase 1 ClinicalTeneobio IncMultiple Myeloma
Details
anti-BCMA CAR T-cell therapy (National Cancer Institute)Phase 1 ClinicalNational Cancer InstituteMultiple Myeloma
Details
BCMA-CS1 cCAR T-cell therapyPhase 1 ClinicaliCell Gene Therapeutics LLCMultiple Myeloma
Details
dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College)Phase 1 ClinicalTongji Medical CollegeMultiple Myeloma
Details
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)Phase 1 ClinicalWuhan Si'an Medical Technology Co LtdMultiple Myeloma
Details
IM-21IM21; IM-21Phase 1 ClinicalBeijing Yimiao Medical Technology Co LtdMultiple Myeloma
Details
SibeprenlimabVIS-649Phase 3 ClinicalVisterra IncGlomerulonephritis, IGA; Glomerulonephritis
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAlpine Immune Sciences IncAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis
Details
ZigakibartBION-1301; FUB523; FUB-523Phase 3 ClinicalAduro Biotech IncGlomerulonephritis, IGA; Proteinuria; Multiple Myeloma
Details
AtaciceptTACI-IgPhase 3 ClinicalZymogenetics IncGlomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic
Details
BAFFR-CAR T cell therapy (PeproMene Bio Inc)PMB-CT01; PMB-101Phase 1 ClinicalPeproMene Bio Inc, City Of Hope National Medical CenterLymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute
Details
JH-013JH-013Phase 1 ClinicalBiotech Pharmaceuticals Co LtdHematologic Neoplasms; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Erythematosus, Systemic
Details
AUR-200AUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma IncAutoimmune Diseases
Details
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityLymphoma, B-Cell; Autoimmune Diseases
Details
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic)MC10029; MC-10029Phase 1 ClinicalMayo ClinicLymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell
Details
ESG-206ESG-206Phase 2 ClinicalShanghai Escugen Biotechnology Co LtdPurpura, Thrombocytopenic, Idiopathic; Lymphoma, B-Cell; Neoplasms
Details
Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University)BAFFR CARTPhase 2 ClinicalThe General Hospital Of Tianjin Medical UniversityNeuromyelitis Optica
Details
IanalumabVAY-736; NOV-5; NVP-VAY736Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgAnemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocytopenia; Scleroderma, Diffuse; Lymphoma, Non-Hodgkin; Hepatitis, Autoimmune; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Arthritis, Rheumatoid; Sjogren's Syndrome; Lymphoma, B-Cell, Marginal Zone; Purpura, Thrombocytopenic, Idiopathic
Details
CT-0590(The First Affiliated Hospital Of Soochow University)CT-0590ClinicalCARsgen Therapeutics Holdings LtdMultiple Myeloma
Details
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)UTAA17ClinicalPersongen Biotherapeutics (Suzhou) Co LtdMultiple Myeloma
Details
PD-1Ab21-BCMACAR-T (CD biopharma)CD-003; CD-203ClinicalMultiple Myeloma
Details
Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)ClinicalMultiple Myeloma
Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics)ACT-001(Acellytron Therapeutics)ClinicalAcellytron TherapeuticsMultiple Myeloma
Details
SA-102SA-102; SA102ClinicalWuhan Si'an Medical Technology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co LtdHematologic Neoplasms
Details
CC-98633CC-98633Phase 1 ClinicalCelgene CorpMultiple Myeloma
Details
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology)Phase 1 ClinicalHebei Senlang Biological Technology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine)Phase 1 ClinicalPersongen BiotherapeuticsMultiple Myeloma
Details
C-4-29Phase 1 ClinicalChongqing Precision Biotechnology Co LtdCarcinoma, Renal Cell; Multiple Myeloma
Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)Phase 1 ClinicalZhejiang University, Shanghai YaKe Biotechnology Co LtdNephritis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin
Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)LCAR-BCXPhase 1 ClinicalNanjing Legend Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital)Phase 1 ClinicalChongqing Xinqiao HospitalMultiple Myeloma
Details
JWCAR129JWCAR129; JWCAR-129Phase 1 ClinicalSuzhou Yaomingjunuo Biotechnology Co LtdMultiple Myeloma
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
AUTO-8AUTO-8; AUTO8Phase 1 ClinicalAutolus Therapeutics Plc, University College LondonMultiple Myeloma
Details
ALLO-605ALLO-605; ALLO605Phase 1 ClinicalCellectis Sa, Overland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
BCMA-UCART cell therapy (Shanghai Bioray Laboratory)Phase 1 ClinicalBRL Medicine IncPolyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis; Multiple Myeloma; Multiple Sclerosis; Neuromyelitis Optica
Details
MCM-998MCM-998; LXG-250Phase 1 ClinicalNovartis Pharma AgMultiple Myeloma
Details
KJ-C2111KJ-C2111; CT-0590Phase 1 ClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
BCMA-NKEBCMA-NKEPhase 1 ClinicalBristol-Myers Squibb CompanyMultiple Myeloma
Details
IBI-346IBI-346Phase 1 ClinicalInnovent Biologics(Suzhou) Co LtdMultiple Myeloma
Details
MEDI-2228MEDI-2228Phase 1 ClinicalMedimmune LlcMultiple Myeloma
Details
HY-027HY-027Phase 1 ClinicalJuventas Cell Therapy LtdMultiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalZhejiang University, OriCell Therapeutics Co LtdMultiple Myeloma
Details
ISB-2001ISB-2001Phase 1 ClinicalIchnos Sciences SaMultiple Myeloma
Details
MCARH-125MCARH-125Phase 1 ClinicalMemorial Sloan Kettering Cancer CenterMultiple Myeloma
Details
TQB-2934TQB2934; TQB-2934Phase 1 ClinicalMultiple Myeloma
Details
Universal BCMA-CD19 CART cell therapy(BRL Medicine)BRL-302Phase 1 ClinicalBRL Medicine IncMyasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Solid tumours; Autoimmune Diseases; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Prostatic Neoplasms
Details
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co)Phase 1 ClinicalNanjing Legend Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalEugia Pharma Specialities Ltd, Actavis IncMultiple Myeloma
Details
BelantamabGSK2857914; GSK-2857914Phase 1 ClinicalGlaxosmithkline PlcAutoimmune Diseases; Multiple Myeloma
Details
Anti-BCMA CAR T (Nanjing Kati Medical Technology)Phase 1 ClinicalNanjing Kati Medical Technology Co LtdMultiple Myeloma
Details
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)SWK001; SWK-001Phase 1 ClinicalHunan Siweikang Pharmaceutical Co LtdMultiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)CBG-002 CAR-TPhase 1 ClinicalCarbiogene Therapeutics Co LtdMultiple Myeloma
Details
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)Phase 1 ClinicalHualan Genetic Engineering (Henan) Co LtdMultiple Myeloma
Details
SIM-0500SIM0500; SIM-0500Phase 1 ClinicalSimcere Pharmaceutical Group LtdBone Marrow Neoplasms; Multiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
C-CAR168 CAR T-cell therapy (AbelZeta)C-CAR168Phase 1 ClinicalCellular Biomedicine (Shanghai) Co LtdMyasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases
Details
YKST-02YKST02; YKST-02Phase 1 ClinicalExcyte Biopharma LtdMultiple Myeloma
Details
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)FKC-288; FKC288Phase 1 ClinicalNanjing University School Of MedicineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Immunoglobulin G4-Related Disease; Lupus Nephritis
Details
SYS-6020SYS6020; SYS-6020Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdMyasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic
Details
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital)Phase 1 ClinicalWuhan Union HospitalLupus Erythematosus, Systemic
Details
BCMA CAR-NK (Hrain Biotechnology)HR012Phase 1 ClinicalHrain Biotechnology Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
Zirconium-89 belantamab89Zr-GSK2857914Phase 1 ClinicalGlaxosmithkline PlcNeoplasms; Multiple Myeloma
Details
Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityLupus Nephritis; Lupus Erythematosus, Systemic
Details
OL-101OL-101Phase 1 ClinicalOverland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
BZE-2204BZE2204; BZE-2204Phase 1 ClinicalShanghai Cell Therapy Group Co LtdLymphoma, B-Cell; Multiple Myeloma
Details
PRG-2311PRG-2311Phase 1 ClinicalImmunoglobulin G4-Related Disease; Lupus Nephritis
Details
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineNephrosis
Details
REVO-UWD-00BREVO-UWD-00B; UWD-00BPhase 1 ClinicalWondercel Therapeutics Co LtdMultiple Myeloma
Details
ESO-T01ESO-T01Phase 1 ClinicalMultiple Myeloma
Details
UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center)Phase 1 ClinicalUniversity Hospitals Cleveland Medical CenterMultiple Myeloma
Details
68Ga-BC168Ga-BC1Phase 1 ClinicalThe First Affiliated Hospital Of Beijing UniversityMultiple Myeloma; Neoplasms, Plasma Cell
Details
Universal allogeneic anti-CD19/BCMA CAR T-cells therapy(XiNiao Biotechnology)Phase 1 ClinicalHangzhou XiNiao Biotechnology Co LtdAnemia, Hemolytic, Autoimmune
Details
RD06-05RD06-05Phase 1 ClinicalNanjing Bioheng Biotech Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Lupus Erythematosus, Systemic
Details
Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)KN5601; KN-5601Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineNephrosis; Autoimmune Diseases; Lupus Erythematosus, Systemic
Details
P-BCMA-ALLO1P-BCMA-ALLO1; RG-6538Phase 1 ClinicalJanssen Biotech Inc, Transposagen Biopharmaceuticals IncMultiple Myeloma
Details
FT-576FT-576Phase 1 ClinicalUniversity Of Minnesota, Fate Therapeutics IncBone Marrow Neoplasms; Multiple Myeloma
Details
CB-011CB-011Phase 1 ClinicalCaribou Biosciences IncMultiple Myeloma
Details
ACLX-001ACLX-001Phase 1 ClinicalArcellx IncMultiple Myeloma
Details
Descartes-15Descartes-015; Descartes-15Phase 1 ClinicalCartesian Therapeutics IncSolid tumours; Multiple Myeloma; Autoimmune Diseases of the Nervous System
Details
DXC-009DXC-009Phase 1 ClinicalHangzhou Dac Biotech Company LtdMultiple Myeloma
Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)Phase 1 ClinicalShengyan Pharmaceutical TechnologyMultiple Myeloma
Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdMultiple Myeloma; Lupus Erythematosus, Systemic; Pancytopenia; Waldenstrom Macroglobulinemia
Details
CART-BCMAMTV-273; CART-BCMAPhase 1 ClinicalUniversity Of PennsylvaniaRejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic
Details
PavurutamabAMG-701Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
AlnuctamabCC-93269; EM-901; BMS-986349Phase 1 ClinicalEngmab AgMultiple Myeloma
Details
ALLO-715ALLO-715Phase 1 ClinicalCellectis SaMultiple Myeloma
Details
PacanalotamabAMG-420; BI-836909Phase 1 ClinicalMicromet IncMultiple Myeloma
Details
Ispectamab debotansineCC-99712; BMS-986352; SP-8919Phase 1 ClinicalCelgene CorpMultiple Myeloma
Details
AMG-224AMG-224Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
bb-21217bb-21217Phase 1 ClinicalBluebird Bio Inc, Bristol-Myers Squibb CompanyMultiple Myeloma
Details
ACTR 087/SEA BCMA combination therapyPhase 1 ClinicalUnum Therapeutics IncMultiple Myeloma
Details
BCMA TriTACHPN-217Phase 1 ClinicalHarpoon Therapeutics, Abbvie IncMultiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdNeoplasms; Multiple Myeloma
Details
NXC-201HBI-0101; NXC-201Phase 2 ClinicalHadassah Medical Organization, Immix Biopharma IncImmunoglobulin Light-chain Amyloidosis; Multiple Myeloma
Details
EMB-06EMB-06; EMB06; CN106; CND106; CND-106Phase 2 ClinicalShanghai Epimab Biotherapeutics, IncMultiple Myeloma; Pemphigus
Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical)Phase 2 ClinicalShandong New Time Pharmaceutical Co LtdMultiple Myeloma
Details
PHE-885PHE-885Phase 2 ClinicalNovartis Pharma AgHematologic Neoplasms; Multiple Myeloma
Details
CM-336(Connaught Biomedical Technology)CM-336; OM336Phase 2 ClinicalKeymed Biosciences Co LtdPurpura, Thrombocytopenic, Idiopathic; Multiple Myeloma
Details
GR-1803GR-1803Phase 2 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co LtdMultiple Myeloma
Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
Descartes-11Descartes-11; Descartes-011Phase 2 ClinicalCartesian Therapeutics IncMultiple Myeloma
Details
ARI-0002hARI-0002hPhase 2 ClinicalInstituto De Salud Carlos IiiMultiple Myeloma
Details
CAR-BCMA(Sheba Medical Center)Phase 2 ClinicalSheba Medical Center, IsraelMultiple Myeloma
Details
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
CART-BCMA(Simnova)SNC-102(Simnova); SNC102(Simnova)Phase 2 ClinicalShanghai Simnova Biotechnology Co LtdMultiple Myeloma
Details
SAR445514SAR445514; SAR-445514; IPH6401/SAR'514Phase 2 ClinicalSanofiImmunoglobulin Light-chain Amyloidosis; Multiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co LtdMultiple Myeloma
Details
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases HospitalMultiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co LtdMultiple Myeloma
Details
IBI-3003IBI3003; IBI-3003Phase 2 ClinicalInnovent Biologics(Suzhou) Co LtdMultiple Myeloma
Details
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)Phase 2 ClinicalShahid Beheshti University Of Medical SciencesMultiple Myeloma
Details
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)Phase 2 ClinicalEssen BiotechGranulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Autoimmune Diseases; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic
Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of HealthPlasmacytoma; Multiple Myeloma
Details
Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdMultiple Myeloma
Details
BCD-248BCD-248Phase 2 ClinicalBIOCAD JSCMultiple Myeloma
Details
Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)Phase 2 ClinicalThe First Affiliated Hospital Of Xiamen UniversityHematologic Neoplasms; Multiple Myeloma
Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)Phase 2 ClinicalPeking University People'S HospitalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Lupus Erythematosus, Systemic; Acquired thrombotic thrombocytopenic purpura; Behcet Syndrome
Details
REGN-5459REGN-5459Phase 2 ClinicalRegeneron Pharmaceuticals IncMultiple Myeloma; Renal Insufficiency, Chronic
Details
HDP-101HDP-101; HDP101-ATACPhase 2 ClinicalHeidelbergHematologic Diseases; Paraproteinemias; Multiple Myeloma
Details
KQ-2003KQ-2003; KQ2003Phase 2 ClinicalShanghai Keqi Pharmaceutical Technology Co LtdSolid tumours; Multiple Myeloma; POEMS Syndrome
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military ServiceMultiple Myeloma
Details
GC-012FGC-012F; GC012F; AZD-0120; AZD0120Phase 2 ClinicalGracell Biotechnologies (Shanghai) Co LtdMyasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin
Details
Orvacabtagene autoleucelET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125Phase 2 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
C-CAR088C-CAR088Phase 2 ClinicalCellular Biomedicine (Shanghai) Co LtdMultiple Myeloma
Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdPlasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell
Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdLymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin
Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology)BCMA-CART; HR003Phase 2 ClinicalHrain Biotechnology Co LtdMultiple Myeloma
Details
BCMA CAR-T Cells (Pregene)PRG-1801; GLPG-5301; DRL-1801Phase 2 ClinicalPurpura, Thrombocytopenic, Idiopathic; Immunoglobulin G4-Related Disease; Multiple Myeloma; Lupus Nephritis
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian)Descartes-08Phase 3 ClinicalCartesian Therapeutics IncMyasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic
Details
CD3 and B-cell maturation antigen T-cell engaging bispecific antibody (AbbVie/TeneoOne)ABBV-383; TNB-383BPhase 3 ClinicalTeneoOne IncImmunoglobulin Light-chain Amyloidosis; Multiple Myeloma
Details
Anitocabtagene autoleucelKite-772; CART-ddBCMAPhase 3 ClinicalArcellx IncMyasthenia Gravis; Neuromuscular Manifestations; Autoimmune Diseases; Multiple Myeloma; Muscular Diseases; Muscle Weakness; Autoimmune Diseases of the Nervous System
Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University)Phase 3 ClinicalThe First Affiliated Hospital Of Soochow UniversityLeukemia; Multiple Myeloma
Details
Autologous CAR-T cell therapy expressing the BAFF-ligandLMY-920; LUMT1A22Phase 1 ClinicalLuminary Therapeutics IncLymphoma, B-Cell; Sjogren's Syndrome; Scleroderma, Systemic; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell
Details
UBP-1213UBP-1213; UBP 1213scPhase 1 ClinicalWuhan Huaxin Kangyuan Biomedicine Co LtdLupus Erythematosus, Systemic
Details
TabalumabLY-2127399Phase 2 ClinicalEli Lilly And CompanyMultiple Sclerosis, Relapsing-Remitting; Dermatomyositis; Scleroderma, Systemic; Arthritis, Rheumatoid; Autoimmune Diseases; Multiple Sclerosis; Arthritis, Juvenile; Multiple Myeloma; Connective Tissue Diseases; Lupus Erythematosus, Systemic; Pemphigus; Kidney Failure, Chronic
Details
Rozibafusp alfaMEDI-0700; AMG-570Phase 2 ClinicalAmgen IncArthritis, Rheumatoid; Lupus Erythematosus, Systemic
Details
TibulizumabLY-3090106; LY3090106; ZB-106Phase 2 ClinicalEli Lilly And CompanySjogren's Syndrome; Arthritis, Rheumatoid; Scleroderma, Systemic; Sjogren-Larsson Syndrome
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAlpine Immune Sciences IncAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis
Details
AtaciceptTACI-IgPhase 3 ClinicalZymogenetics IncGlomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic
Details

Resources

  • Background
  • Product Features
  • Product List
  • Validated Data
  • Clinical Drug Information Table of BAFF-APRIL Pathway
  • Resources
Kontaktieren Sie uns